Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 178-186

  Rowinsky, Eric K ^a   Humphrey, Rachel ^a   Hammond, Lisa A ^a   Aylesworth, Cheryl ^a   Smetzer, Leslie ^a   Hidalgo, Manuel ^a   Morrow, Mark ^a   Smith, Lon ^a   Garner, Allison ^a   Sorensen, J Mel ^a   Von Hoff, Daniel D ^a   Eckhardt, S Gail ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; TANOMASTAT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; ENZYME SPECIFICITY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN FAMILY; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0033986165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.178     Document Type: Article

References (48)

1. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14:455-463, 1992
2. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270, 1997
3. Birkedal-Hansen H, Moore WG, Booden MK, et al: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4:197-250, 1993
4. Denis LJ, Verweij J: Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest New Drugs 15:175-185, 1997
5. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr: Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastases. FASEB J 7:1434-1441, 1993
6. Stetler-Stevenson WG, Krutzsch HC, Liotta L: Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase inhibitor family. J Biol Chem 264:17374-17378, 1989
7. Leco KJ, Khokha R, Pavloff N, et al: Tissue inhibitor of metalloproteinases-3 (TIMP-3) as an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269:9352-9360, 1994
8. Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51:5054s-5059s, 1991 (suppl 18)
9. Tryggvason K, Hoyhtya M, Pyke C: Type IV collagenase in invasive tumors. Breast Cancer Res Treat 24:209-218, 1993
10. Liotta LA, Thorgeirsson UP, Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 3:361-372, 1984
11. Ray JM, Stetler-Stevenson WG: The role of metalloproteinases and their inhibitors in tumour invasion, metastasis, and angiogenesis. Eur Respir J 7:2062-2072, 1994
12. Khokha R, Martin DC, Fata JE: Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Cancer Metastasis Rev 14:97-111, 1995
13. Watson SA, Morris TM, Robinson G, et al: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56:2815-2822, 1996
14. Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92 kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91:4293-4297, 1994
15. Zeng ZS, Guillem JG: Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase I mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 67:1126-1131, 1993
16. Zeng ZS, Huang Y, Cohen AM, et al: Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14:3133-3140, 1996
17. Friedman R, Toth M, Pena D, et al: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55:2528-2555, 1995
18. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336, 1991
19. Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908-917, 1995
20. Wojtowicz-Praga S, Torri J, Johnson M, et al: Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16:2150-2156, 1998
21. Moutsiakis D, Mancuso P, Krutzsch H, et al: Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connective Tissue Res 28:213-230, 1992
22. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75, 1997
23. Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharm Ther 75:69-75, 1997
24. Hibner B, Card A, Flynn C, et al: BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Assoc Cancer Res 39:302, 1998 (abstr 2063)
25. Hibner B, Bull C, Flynn C, et al: Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous and metastatic in vivo models. Ann Oncol 9:75, 1998 (suppl 2)
26. Bull C, Flynn C, Eberwein D, et al: Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models. Proc Am Assoc Cancer Res 39:302, 1998 (abstr 2062)
27. Gatto C, Rieppi M, Borsotti P, et al: Anti-angiogenic activity of BAY 12-9566, an inhibitor of matrix metalloproteinase. Ann Oncol 9:74, 1998 (suppl 2)
28. Flynn C, Bull C, Eberwein D, et al: Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT116 orthotopic model. Proc Am Assoc Cancer Res 39:301, 1998 (abstr 2057)
29. Flynn C, Bull C, Matherne C, et al: Anti-invasive and antimetastatic activity of the novel MMP inhibitor BAY 12-9566 in subcutaneous and orthotopic models using the human colon carcinoma, HCT 116. Ann Oncol 9:75, 1998 (suppl 2)
30. Clemens GR, Detzer K, Bomhard E, et al: Preclinical drug safety profile for the anti-metastatic matrix metalloproteinase inhibitory agent BAY 12-9566. Ann Oncol 9:74, 1998 (suppl 2)
31. Shah A, Sundaresan P, Humphrey R, et al: Comparative pharmacokinetics of BAY 12-9566, a metalloproteinase inhibitor, in healthy volunteers and cancer patients. Proc Am Assoc Cancer Res 39:521, 1998 (abstr 3547)
32. Brubaker WF, Perrino P, Wu W, et al: Pharmacokinetics of BAY 12-9566 in animals: Species comparison. Proc Am Assoc Can Res 40:391, 1999 (abstr 2589)
33. Agarwal VK, Rose DL, Krol GJ: Quantitative HPLC analysis of 4-[4-4-(chloropheyl)phenyl]-4-oxo-2S-(phenylthiomethyl) butanoic acid (BAY 12-9566), a metalloproteinase inhibitor and its metabolites in human plasma. J Liq Chromo Rel Technol 22:1893-1906, 1999
34. Neumanaitis J, Poole C, Primrose J, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin Can Res 45:1101-1119, 1998
35. Millar AW, Brown PD, Moore J, et al: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 45:21-26, 1998
36. Erlichman C, Adjei A, Alberts, S, et al: Phase I study of BAY 12-9566: A matrix metalloproteinase inhibitor. Proc Am Soc Clin Oncol 17:217a, 1998 (abstr 837)
37. Grochow LB, O'Reilly S, Humphrey R, et al: Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566. Proc Am Soc Clin Oncol 17:213a, 1998 (abstr 822)
38. Goel R, Hirte H, Goel R, et al: Phase I study of the matrix metalloproteinase inhibitor (MMPI) BAY 12-9566 in patients with advanced cancer. Proc Am Soc Clin Oncol 17:217a, 1998 (abstr 840)
39. Azzam HS, Arand G, Lippman ME, et al: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758-1764, 1993
40. Zucker S, Lysik RM, Zarrabi HM, et al: Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer: Potential use in predicting metastasis and monitoring treatment. Ann NY Acad Sci 732:248-262, 1994
41. Levy TD, Cioce V, Sobel ME, et al: Increased expression of the Mr 72,000 type IV collagenase in human colonie adenocarcinoma. Cancer Res 51:439-444, 1994
42. r 92,000 type IV collagenase is increased in plasma of patients with colon and breast cancer. Cancer Res 53:140-146, 1993
43. Brown PD, Bloxidge RE, Stuart NSA, et al: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 85:574-578, 1993
44. Iizasa T, Fujisawa T, Suzuki M, et al: Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 5:149-153, 1999
45. Moses M, Wiederschain D, Loughlin KR, et al: Increased incidence of matrix metalloproteinases in urine and cancer patients. Cancer Res 58:1395-1399, 1998
46. Wojtowicz-Praga S, Low J, Marshall J, et al: Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drug 14:193-202, 1996
47. Moutsiakis D, Mancuso P, Krutzsch H, et al: Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connective Tissue Res 28:213-230, 1992
48. Zucker S, Lysik RM, Zarrabi MH, et al: Type IV collagenase/ gelatinase (MMP-2) is not increased in plasma of patients with cancer. Cancer Epidemiol Biomarkers Prev 1:475-479, 1992